Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$45.95M$45.95Mno prior Q3 2016 on file Net Income-$47.73M-$47.73MN/M vs Q3 2016 EPS Diluted-$0.78-$0.78N/M vs Q3 2016 Operating Income-$45,907,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$58,668,000N/M Margins · derivedOperating margin-99.9%
Net margin-103.9%
ended Sep 30, 2017 · filed Nov 1, 2017 · 32 d after period end